Index RUT
P/E -
EPS (ttm) -1.49
Insider Own 56.63%
Shs Outstand 49.12M
Perf Week 0.00%
Market Cap 187.64M
Forward P/E -
EPS next Y -0.52
Insider Trans -0.13%
Shs Float 21.41M
Perf Month -19.66%
Income -63.32M
PEG -
EPS next Q -0.29
Inst Own 29.86%
Short Float 4.72%
Perf Quarter -21.65%
Sales 96.63M
P/S 1.94
EPS this Y 41.37%
Inst Trans 3.90%
Short Ratio 5.56
Perf Half Y 10.79%
Book/sh 1.09
P/B 3.47
EPS next Y 37.52%
ROA -35.53%
Short Interest 1.01M
Perf Year -43.45%
Cash/sh 1.68
P/C 2.26
EPS next 5Y -
ROE -112.72%
52W Range 3.04 - 8.80
Perf YTD -22.13%
Dividend Est. -
P/FCF -
EPS past 5Y -37.60%
ROI -46.55%
52W High -56.82%
Beta 1.52
Dividend TTM -
Quick Ratio 2.94
Sales past 5Y 23.82%
Gross Margin 49.92%
52W Low 25.00%
ATR (14) 0.23
Dividend Ex-Date -
Current Ratio 3.45
EPS Y/Y TTM 20.57%
Oper. Margin -57.98%
RSI (14) 30.70
Volatility 3.53% 5.16%
Employees 330
Debt/Eq 1.59
Sales Y/Y TTM 29.09%
Profit Margin -65.53%
Recom 1.38
Target Price 9.00
Option/Short Yes / Yes
LT Debt/Eq 1.53
EPS Q/Q 55.71%
Payout -
Rel Volume 0.51
Prev Close 3.82
Sales Surprise 1.34%
EPS Surprise 18.15%
Sales Q/Q 24.83%
Earnings Mar 04 AMC
Avg Volume 181.97K
Price 3.80
SMA20 -8.19%
SMA50 -20.75%
SMA200 -22.22%
Trades
Volume 93,172
Change -0.52%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-14-23 Initiated
Guggenheim
Neutral
Jul-05-23 Resumed
JP Morgan
Overweight
$18
Feb-02-23 Initiated
UBS
Buy
$14
Nov-03-22 Initiated
CapitalOne
Overweight
$19
Oct-06-22 Initiated
Stephens
Overweight
$16
Jun-22-22 Initiated
BTIG Research
Buy
$16
Jan-06-22 Resumed
Piper Sandler
Overweight
$23
May-11-21 Initiated
Piper Sandler
Overweight
$28
May-11-21 Initiated
Morgan Stanley
Overweight
$26
May-11-21 Initiated
JP Morgan
Overweight
$23
May-11-21 Initiated
Canaccord Genuity
Buy
$25
Show Previous Ratings
Apr-22-24 04:05PM
Apr-05-24 08:00AM
Mar-05-24 09:52AM
07:00AM
(Thomson Reuters StreetEvents)
Mar-04-24 08:51PM
05:31PM
Loading…
05:31PM
05:15PM
04:21PM
(Associated Press Finance)
04:05PM
Feb-08-24 04:05PM
Feb-07-24 04:13AM
Jan-18-24 08:00AM
Jan-10-24 08:00AM
Jan-08-24 01:07AM
Jan-07-24 08:00AM
08:00AM
Loading…
08:00AM
08:00AM
Jan-05-24 08:34AM
Dec-27-23 09:55AM
Dec-20-23 08:05AM
Nov-12-23 10:51AM
Nov-09-23 10:25AM
(Thomson Reuters StreetEvents) +10.90%
Nov-08-23 05:51PM
04:05PM
(Associated Press Finance)
04:00PM
Nov-02-23 08:00AM
Nov-01-23 10:01AM
Oct-31-23 09:00AM
Oct-17-23 10:22AM
Oct-11-23 04:05PM
08:00AM
Loading…
Sep-19-23 08:00AM
Aug-17-23 09:56AM
Aug-08-23 12:38PM
(Thomson Reuters StreetEvents)
Aug-07-23 06:15PM
05:02PM
(Associated Press Finance)
04:05PM
08:05AM
Aug-06-23 10:57AM
Jul-26-23 04:05PM
Jul-21-23 09:21AM
Jul-12-23 09:55AM
08:05AM
Jul-10-23 10:08AM
Jun-13-23 07:58PM
12:32PM
08:29AM
06:37AM
Jun-12-23 04:05PM
Jun-08-23 12:55AM
Jun-07-23 04:08PM
May-09-23 10:43AM
(Thomson Reuters StreetEvents)
May-08-23 05:35PM
04:32PM
04:05PM
May-05-23 07:36AM
Apr-27-23 08:00AM
Apr-17-23 12:20PM
Apr-14-23 03:38PM
Apr-12-23 08:00AM
08:00AM
Apr-06-23 08:00AM
Mar-20-23 04:00PM
Mar-09-23 05:17AM
Mar-08-23 07:21AM
Mar-07-23 09:52AM
(Thomson Reuters StreetEvents)
Mar-06-23 05:35PM
04:05PM
Feb-28-23 08:00AM
Feb-27-23 10:00AM
Feb-10-23 06:36PM
Feb-06-23 08:05AM
Feb-01-23 08:00AM
Jan-08-23 04:00PM
Jan-06-23 08:00AM
Dec-28-22 04:00PM
Dec-15-22 04:00PM
Dec-07-22 05:15AM
Nov-07-22 05:25PM
04:05PM
04:05PM
Nov-03-22 08:05AM
Oct-11-22 08:05AM
06:34AM
Oct-06-22 01:40PM
Aug-31-22 08:05AM
Aug-11-22 05:24PM
Aug-09-22 12:00AM
Aug-08-22 05:55PM
04:05PM
Jul-27-22 08:05AM
Jul-12-22 08:05AM
Jul-01-22 07:53AM
Jun-29-22 07:21AM
Jun-28-22 08:05AM
Jun-16-22 08:41AM
Jun-03-22 06:11AM
Jun-01-22 08:05AM
May-11-22 06:10AM
May-06-22 10:00PM
May-05-22 06:15PM
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. The company was founded by Garry Nolan, Yury Goltsev and Nikolay Samusik in 2015 and is headquartered in Marlborough, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
McKelligon Brian President and CEO Mar 20 '24 Option Exercise 0.30 7,500 2,272 239,368 Mar 22 05:54 PM McKelligon Brian President and CEO Mar 20 '24 Sale 4.97 7,500 37,243 231,868 Mar 22 05:54 PM McKelligon Brian President and CEO Mar 13 '24 Sale 4.94 7,500 37,035 224,368 Mar 14 08:41 PM McKelligon Brian President and CEO Dec 19 '23 Option Exercise 0.30 7,500 2,272 160,063 Dec 20 07:16 PM McKelligon Brian President and CEO Dec 19 '23 Sale 4.48 7,500 33,566 152,563 Dec 20 07:16 PM McKelligon Brian President and CEO Dec 12 '23 Option Exercise 0.30 7,500 2,272 160,063 Dec 14 04:24 PM McKelligon Brian President and CEO Dec 12 '23 Sale 4.25 7,500 31,871 152,563 Dec 14 04:24 PM McKelligon Brian President and CEO Nov 20 '23 Option Exercise 0.30 7,500 2,272 160,063 Nov 22 04:00 PM McKelligon Brian President and CEO Nov 20 '23 Sale 4.39 7,500 32,901 152,563 Nov 22 04:00 PM Pla Frederic Chief Operating Officer Sep 07 '23 Buy 4.60 20,000 92,014 20,000 Sep 11 04:00 PM Raffin Thomas A. Director Jun 12 '23 Buy 5.00 2,020,000 10,100,000 15,937,535 Jun 12 06:15 PM Winkler Matthew Director Jun 12 '23 Buy 5.00 203,388 1,016,940 984,513 Jun 12 06:16 PM SHEPLER ROBERT G Director Jun 12 '23 Buy 5.00 120,000 600,000 369,592 Jun 12 06:16 PM Ek John Frederick CFO Jun 12 '23 Buy 5.00 20,000 100,000 20,000 Jun 12 06:18 PM Mendel Scott Director Jun 12 '23 Buy 5.00 20,000 100,000 28,500 Jun 12 06:17 PM LAI GOLDMAN MYLA Director Jun 12 '23 Buy 5.00 20,000 100,000 20,000 Jun 12 06:18 PM McKelligon Brian President/CEO Jun 06 '23 Option Exercise 0.30 5,000 1,515 157,563 Jun 06 09:45 PM McKelligon Brian President/CEO Jun 06 '23 Sale 5.71 5,000 28,537 152,563 Jun 06 09:45 PM
Index -
P/E -
EPS (ttm) -4.19
Insider Own 39.29%
Shs Outstand 8.10M
Perf Week 6.95%
Market Cap 22.46M
Forward P/E -
EPS next Y -1.99
Insider Trans -0.08%
Shs Float 4.92M
Perf Month -1.77%
Income -34.03M
PEG -
EPS next Q -1.14
Inst Own 25.28%
Short Float 5.83%
Perf Quarter -3.65%
Sales 2.05M
P/S 10.96
EPS this Y 34.26%
Inst Trans 7.93%
Short Ratio 14.36
Perf Half Y -30.58%
Book/sh 3.37
P/B 0.82
EPS next Y 27.51%
ROA -60.27%
Short Interest 0.29M
Perf Year -11.92%
Cash/sh 4.45
P/C 0.62
EPS next 5Y 15.20%
ROE -78.34%
52W Range 2.41 - 4.55
Perf YTD -12.89%
Dividend Est. -
P/FCF -
EPS past 5Y 20.27%
ROI -101.27%
52W High -39.12%
Beta 0.67
Dividend TTM -
Quick Ratio 5.69
Sales past 5Y 106.75%
Gross Margin 97.85%
52W Low 14.94%
ATR (14) 0.17
Dividend Ex-Date -
Current Ratio 5.69
EPS Y/Y TTM -12.62%
Oper. Margin -1785.18%
RSI (14) 52.36
Volatility 4.36% 6.15%
Employees 33
Debt/Eq 0.24
Sales Y/Y TTM 34.67%
Profit Margin -1659.39%
Recom 1.00
Target Price 22.50
Option/Short No / Yes
LT Debt/Eq 0.23
EPS Q/Q -17.01%
Payout -
Rel Volume 0.03
Prev Close 2.76
Sales Surprise -
EPS Surprise -1.93%
Sales Q/Q 61.33%
Earnings Mar 07 AMC
Avg Volume 19.98K
Price 2.77
SMA20 2.79%
SMA50 -2.57%
SMA200 -11.10%
Trades
Volume 688
Change 0.36%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-11-21 Upgrade
Stifel
Hold → Buy
$4 → $24
Dec-03-20 Initiated
Cantor Fitzgerald
Buy
$32
Aug-26-20 Initiated
Piper Sandler
Overweight
$26
Aug-17-20 Resumed
ROTH Capital
Buy
$51
Aug-04-20 Initiated
H.C. Wainwright
Buy
$33
Apr-18-24 04:05PM
Mar-20-24 08:00AM
Mar-08-24 02:06PM
Mar-07-24 09:54PM
04:01PM
09:00AM
Loading…
Feb-26-24 09:00AM
Feb-05-24 04:05PM
Jan-04-24 04:05PM
Nov-21-23 04:15PM
Nov-20-23 04:05PM
Nov-07-23 04:35PM
04:01PM
Sep-26-23 09:00AM
Sep-14-23 08:00AM
Sep-07-23 04:34PM
09:00AM
Loading…
Aug-22-23 09:00AM
Aug-09-23 04:01PM
Jul-26-23 09:00AM
Jul-12-23 08:00AM
Jun-28-23 04:01PM
Jun-21-23 09:00AM
May-31-23 08:00AM
May-25-23 08:00AM
May-22-23 09:00AM
May-08-23 08:00AM
May-03-23 04:05PM
Apr-27-23 09:00AM
Apr-19-23 09:00AM
Mar-09-23 04:05PM
Mar-05-23 02:00PM
04:05PM
Loading…
Mar-01-23 04:05PM
Feb-28-23 04:05PM
Feb-15-23 04:05PM
Jan-03-23 09:00AM
Dec-12-22 07:30AM
Nov-29-22 04:05PM
Nov-22-22 04:05PM
Nov-14-22 06:10AM
06:00AM
Sep-26-22 04:05PM
Aug-31-22 09:00AM
Aug-16-22 07:30AM
Aug-09-22 04:01PM
Jul-27-22 04:05PM
Jul-24-22 08:27AM
Jul-20-22 08:32PM
May-16-22 04:05PM
May-10-22 04:01PM
May-06-22 10:25AM
May-05-22 09:00AM
Apr-26-22 09:00AM
Apr-11-22 08:30AM
Mar-23-22 04:05PM
Mar-10-22 04:01PM
09:00AM
Feb-23-22 09:00AM
Feb-14-22 12:05PM
Jan-05-22 09:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-08-21 09:38AM
Nov-24-21 10:00AM
Nov-15-21 11:14AM
Nov-10-21 05:06PM
Nov-08-21 10:42AM
Nov-03-21 04:01PM
Oct-21-21 04:05PM
Sep-02-21 08:00AM
Aug-16-21 09:58AM
Aug-05-21 08:00AM
Aug-03-21 08:00AM
Aug-02-21 08:00AM
Jul-26-21 04:18PM
Jul-22-21 08:00AM
Jul-20-21 04:01PM
Jun-28-21 08:00AM
May-19-21 09:00AM
May-13-21 09:00AM
May-05-21 04:01PM
02:30PM
Apr-28-21 09:00AM
Apr-27-21 08:00AM
Apr-20-21 04:05PM
Apr-14-21 04:05PM
Mar-20-21 11:00AM
Mar-11-21 04:05PM
Mar-09-21 04:05PM
01:30PM
Mar-04-21 09:00AM
Mar-02-21 04:05PM
12:30PM
Feb-22-21 04:15PM
Feb-16-21 04:01PM
Dec-18-20 09:00AM
Dec-16-20 02:19AM
(Simply Wall St.) +15.38%
Nov-30-20 05:35PM
Nov-23-20 07:43PM
Nov-10-20 04:01PM
02:30PM
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
McKew John C. Chief Scientific Officer Apr 03 '24 Sale 2.77 2,214 6,144 17,153 Apr 03 05:10 PM McKew John C. Chief Scientific Officer Feb 06 '24 Sale 3.03 438 1,328 18,403 Feb 07 05:22 PM McKew John C. Chief Scientific Officer Aug 02 '23 Sale 3.21 3,407 10,919 18,707 Aug 03 04:58 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite